#5 Clinical Trend: Pembrolizumab
Recently approved by the US Food and Drug Administration (FDA), pembrolizumab is the first immunomodulator that acts as a programmed death inhibitor. It has been approved for use in patients with advanced or unresectable melanoma who are not responding to other medications.
For more in-depth clinical information, see Pembrolizumab.
Medscape © 2014 WebMD, LLC
Cite this: Top 10 Trends in Medicine, September 2014 - Medscape - Sep 23, 2014.